List of Excipients in Branded Drug ERAXIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Roerig	ERAXIS	anidulafungin	0049-0114	FRUCTOSE	1969-12-31
Roerig	ERAXIS	anidulafungin	0049-0114	HYDROCHLORIC ACID	1969-12-31
Roerig	ERAXIS	anidulafungin	0049-0114	MANNITOL	1969-12-31
Roerig	ERAXIS	anidulafungin	0049-0114	POLYSORBATE 80	1969-12-31
Roerig	ERAXIS	anidulafungin	0049-0114	SODIUM HYDROXIDE	1969-12-31
Roerig	ERAXIS	anidulafungin	0049-0114	TARTARIC ACID	1969-12-31

Eraxis (Anidulafungin) Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Eraxis, the brand formulation of anidulafungin, is an intravenous echinocandin antifungal supplied as a sterile lyophilized powder for reconstitution. Its excipient system is relatively simple: fructose, mannitol, polysorbate 80, and tartaric acid. The strongest commercial opportunities are not conventional oral reformulation plays. They are sterile-product cost reduction, ready-to-use infusion formats, pediatric and renal-dose convenience, improved cold-chain resilience, and differentiated hospital administration systems.

Anidulafungin has no oral formulation because of poor gastrointestinal absorption. Any competitive product must therefore address sterile manufacturing, intravenous compatibility, infusion logistics, and hospital pharmacy workflow. The current Eraxis formulation creates potential room for products that reduce preparation steps while maintaining chemical stability and safety.

What excipients are used in Eraxis?

Eraxis contains anidulafungin with a carbohydrate-based bulking system, a surfactant, and an acidifying agent. The U.S. prescribing information identifies the following inactive ingredients per 100-mg vial:

Excipient	Primary formulation role	Commercial relevance
Fructose	Bulking agent and matrix former in the lyophilized cake	May create labeling and patient-population considerations for hereditary fructose intolerance
Mannitol	Bulking agent and cake-structure contributor	Supports lyophilized appearance and reconstitution performance
Polysorbate 80	Surfactant that limits interfacial adsorption and aggregation	Potential degradation, peroxide, and extractables-control issue
Tartaric acid	pH adjustment and buffering contribution	Helps maintain formulation pH and may affect stability and compatibility

The product is reconstituted with sterile water for injection and then diluted in either 0.9% sodium chloride injection or 5% dextrose injection before intravenous administration. The label limits infusion rates and establishes a defined post-reconstitution and post-dilution handling window.[1]

The excipient strategy is consistent with a conventional lyophilized injectable. It avoids complex amino-acid, lipid, or polymer systems, but the formulation still requires control of surfactant quality, residual moisture, cake integrity, reconstitution time, particulate burden, and infusion compatibility.

How does the Eraxis formulation work in a lyophilized injectable?

The formulation has four technical functions.

First, fructose and mannitol provide solids that support the physical structure of the freeze-dried cake. A robust cake is needed for efficient reconstitution, acceptable visual appearance, and protection during vial transport.

Second, polysorbate 80 reduces adsorption of anidulafungin to vial and administration surfaces. It can also reduce aggregation caused by agitation and air-liquid interfaces. Its use introduces a separate control strategy because polysorbate 80 may contain peroxide impurities and can undergo hydrolysis or oxidation during storage.

Third, tartaric acid helps maintain the formulation environment required for anidulafungin stability. The acid system must be balanced against container closure compatibility and the pH of the final infusion.

Fourth, lyophilization separates the product from the water-driven degradation pathways that would affect a liquid formulation. The tradeoff is higher manufacturing complexity and a mandatory reconstitution step.

Key critical quality attributes

A competing anidulafungin product would likely need to control:

• Assay and degradation products
• Reconstitution time
• Cake collapse or shrinkage
• Residual moisture
• Visible and subvisible particles
• Polysorbate 80 degradation
• Extractable and leachable compounds
• Container closure integrity
• Sterility and bacterial endotoxins
• Diluted-solution stability
• Infusion-line compatibility
• Osmolality and pH
• Adsorption to bags, tubing, and filters

The most defensible formulation-development strategy would use a design-of-experiments program covering surfactant concentration, sugar-to-polyol ratio, buffer concentration, pH, freezing rate, primary-drying temperature, secondary-drying temperature, and residual moisture.

What formulation patents protect Eraxis and anidulafungin?

The commercial protection for Eraxis is likely to have been driven primarily by active-ingredient, formulation, manufacturing, and regulatory exclusivity rights rather than by the basic use of common excipients. Common excipients such as mannitol, fructose, polysorbate 80, and tartaric acid generally offer limited standalone patent leverage because each has extensive prior use in sterile pharmaceutical products.

Potentially relevant patent categories include:

Patent category	Potential protected subject matter	Competitive value
Anidulafungin composition patents	The active compound and related echinocandin structures	High, but generally time-limited
Formulation patents	Specific excipient ratios, pH ranges, concentration ranges, or stability profiles	Moderate to high if claim scope is narrow and technically supported
Lyophilization patents	Freeze-drying cycles, cake structure, residual-moisture limits, or reconstitution performance	Moderate
Manufacturing patents	Fermentation, purification, crystallization, impurity removal, or sterile processing	High for complex API supply
Method-of-use patents	Treatment of candidemia, invasive candidiasis, esophageal candidiasis, or other fungal infections	Variable, depending on claim scope and enforceability
Device or presentation patents	Premixed bags, dual-chamber systems, transfer devices, or administration kits	Commercially relevant for hospital workflow

A formulation built around the same listed excipients does not automatically infringe a formulation patent. Patent analysis would require claim-by-claim review of concentration ranges, pH, reconstitution conditions, lyophilization parameters, and stability limitations. An ANDA sponsor may pursue a Paragraph IV certification against relevant listed patents or a Paragraph III certification where a patent remains in force but the sponsor accepts delayed launch.

The Orange Book should be checked for the current listed patents, pediatric exclusivity, and any active regulatory exclusivity. Patent expiration dates should not be inferred from the brand label or from the original FDA approval date alone.[2]

When does Eraxis lose exclusivity and face generic entry?

Eraxis received FDA approval in 2006 for adults with esophageal candidiasis and invasive candidiasis, including candidemia.[1] The main product is now a mature hospital anti-infective rather than a new-market medicine.

Generic entry depends on several separate dates:

1. The expiration of composition-of-matter and formulation patents.
2. Any remaining method-of-use patents listed in the Orange Book.
3. FDA approval of an ANDA or other abbreviated application.
4. Any 180-day first-filer exclusivity.
5. Regulatory exclusivity, including pediatric exclusivity if applicable.
6. Litigation triggered by a Paragraph IV certification.

For a sterile injectable, approval timing can also be affected by manufacturing-site inspection, aseptic-processing validation, container closure issues, and drug-master-file readiness. A nominal patent expiry does not guarantee immediate supply.

What generic launch scenarios exist for anidulafungin?

Launch scenario	Likely product profile	Commercial effect
Standard generic vial	Lyophilized 100-mg vial with comparable reconstitution	Rapid price competition and hospital formulary substitution
Authorized generic	Brand-equivalent product marketed without the Eraxis brand	Can reduce third-party generic share
Premium generic	Improved packaging, lower reconstitution burden, or stronger supply reliability	Defends price through operational value
Ready-to-use infusion	Diluted sterile product in a bag or dual-chamber container	Competes on pharmacy labor and error reduction
Pediatric presentation	Lower-strength vial or calibrated dose-delivery format	Addresses weight-based dosing and wastage
Contract-manufactured hospital product	Institutional supply with predictable inventory	Targets group purchasing organizations and hospital systems

The standard generic vial is the lowest-risk regulatory route. A ready-to-use infusion or substantially modified liquid product may require more extensive chemistry, manufacturing, and controls data and could fall outside a simple ANDA strategy depending on the proposed differences.

What excipient opportunities exist for an Eraxis competitor?

Polysorbate replacement or optimization

Polysorbate 80 is familiar to regulators and manufacturers, but its degradation profile can complicate long-term stability. A competitor could evaluate polysorbate 20, poloxamers, or other injectable surfactants. The commercial benefit would need to exceed the regulatory burden created by a new excipient system.

A safer strategy may be to retain polysorbate 80 but control its peroxide value, hydrolysis profile, supplier qualification, and storage exposure. A lower surfactant concentration could also reduce impurity and tolerability concerns if adsorption protection remains adequate.

Alternative bulking systems

Mannitol and fructose are functional but not interchangeable. A competitor could investigate sucrose, trehalose, glycine, or combinations of sugar and polyol excipients. The development objective would be a stronger cake, shorter reconstitution time, or improved stability under temperature excursion.

Replacing fructose could provide a labeling advantage for patients with hereditary fructose intolerance. That opportunity would require proof that the new formulation maintains potency, impurity control, and infusion compatibility.

Ready-to-use liquid formulation

A stable liquid anidulafungin product could remove reconstitution and dilution steps. This would be commercially attractive in intensive-care units and hospitals with centralized pharmacy operations.

The technical barrier is high. A liquid product must control hydrolysis, oxidation, adsorption, precipitation, microbial risk, and container interaction over the proposed shelf life. A low-temperature storage requirement could also offset the labor savings. The strongest commercial target would be a product that remains stable at controlled room temperature and is available in a pharmacy-ready bag.

Dual-chamber and closed-system presentations

A dual-chamber vial or bag could separate the drug from the diluent until administration. This format could reduce preparation errors and limit exposure to multiple transfer steps. It may also support a differentiated patent position based on the container, mixing mechanism, or administration sequence.

The main barriers are device development, combination-product requirements, filling-line adaptation, and hospital-system compatibility.

Low-waste pediatric and dose-flexible products

Eraxis dosing is weight-based in pediatric patients and may require manipulation of a 100-mg vial. A lower-strength vial, more concentrated reconstituted solution, or ready-to-use pediatric bag could reduce waste.

This opportunity is commercially narrower than the adult hospital market but may improve formulary acceptance where pediatric fungal infections generate frequent dose adjustments.

How does Eraxis compare with other echinocandins?

Product	Active ingredient	Formulation presentation	Key excipient or administration issue	Commercial comparison
Eraxis	Anidulafungin	Lyophilized IV powder	Reconstitution and dilution required	Potential advantage in hepatic dosing simplicity
Cancidas	Caspofungin	Lyophilized IV powder	More complex reconstitution and infusion preparation	Competes in invasive candidiasis
Mycamine	Micafungin	Lyophilized IV powder	Reconstitution and dilution; formulation-specific handling	Strong hospital and pediatric relevance

Anidulafungin is generally recognized for dosing that does not require adjustment for renal impairment and does not require routine hepatic dose modification in the same manner as some alternatives. That clinical positioning can support premium hospital contracting, but excipient or presentation improvements remain important because all three major echinocandins are intravenous hospital products.[3]

A differentiated anidulafungin product should compete on total administration cost, not only on vial acquisition price. Pharmacy labor, discarded drug, preparation time, cold-chain requirements, and medication-error exposure are relevant components of the economic proposition.

What FDA regulatory pathway applies to an improved anidulafungin product?

A formulation that is pharmaceutically equivalent to Eraxis can generally pursue an ANDA, subject to FDA requirements for sameness, bioequivalence where applicable, sterility, injectable-product quality, and labeling.

A product with a new dosage form, new excipients, a materially different concentration, or a new delivery system may require a 505(b)(2) application. The pathway depends on the extent of reliance on the reference product and the amount of independent clinical or bridging data required.[4]

For sterile injectables, FDA review will focus on:

• Aseptic processing and media-fill validation
• Container closure integrity
• Extractables and leachables
• Particulate and visible-inspection controls
• In-use stability
• Dilution compatibility
• Administration-set compatibility
• Endotoxin and sterility assurance
• Human factors for combination presentations

A ready-to-use bag can have a stronger commercial profile but will face a more demanding development program than a conventional vial.

Which companies are competing in the anidulafungin market?

The competitive field includes the originator and generic injectable manufacturers with sterile fill-finish capacity. Relevant commercial competitors may include the Eraxis brand owner, approved generic sponsors, contract manufacturers, and suppliers of competing echinocandins.

The key competitive variables are:

• FDA approval status
• Orange Book listing status
• Number of approved manufacturers
• Back-order history
• API source and fermentation capacity
• Hospital-contracting access
• GPO participation
• Vial size and packaging
• Reconstitution time
• Stability after dilution
• Product waste
• Geographic registration

Supplier concentration can create an opportunity for a second-source product even when nominal generic prices are low. Hospitals may accept a modest premium for consistent supply of a critical injectable anti-infective.

How strong is the patent estate for an excipient-based Eraxis product?

An excipient-only strategy is unlikely to create a broad blocking patent position. The strongest patent opportunity would combine:

• A defined anidulafungin concentration
• A narrow but clinically useful pH range
• A specific surfactant and stabilizer system
• Demonstrated stability improvement
• A defined lyophilization cycle
• Improved reconstitution or infusion compatibility
• A differentiated container or administration device

Patent strength would depend on unexpected technical results, not merely substitution of one common excipient for another. Claims directed only to routine excipient selection are more vulnerable to obviousness challenges. Claims supported by superior long-term stability, lower impurity formation, reduced adsorption, or measurable pharmacy-efficiency gains are more commercially defensible.

What is the commercial opportunity for Eraxis excipient innovation?

The largest opportunity is a hospital-use product that reduces preparation complexity without introducing a new cold-chain burden. A practical development ranking is:

Opportunity	Technical difficulty	Commercial potential	Regulatory complexity
Equivalent lyophilized generic	Low to moderate	High volume, low margin	Moderate
Improved lyophilized cake and reconstitution	Moderate	Moderate	Moderate
Fructose-free formulation	Moderate	Niche to moderate	Moderate
Reduced-waste pediatric product	Moderate	Niche	Moderate to high
Dual-chamber presentation	High	Moderate to high	High
Ready-to-use liquid infusion	Very high	High if stable	High
Premixed room-temperature bag	Very high	High	High

Revenue exposure for the brand depends on the share of hospital antifungal spending attributable to anidulafungin, the number of approved generic suppliers, contract pricing, and the rate of therapeutic substitution with caspofungin or micafungin. Those variables can change quickly after generic entry.

Key Takeaways

• Eraxis is a lyophilized intravenous anidulafungin product using fructose, mannitol, polysorbate 80, and tartaric acid.
• The excipient system supports cake formation, surfactant protection, pH control, and reconstitution performance.
• The most attractive formulation opportunity is a pharmacy-ready presentation that reduces reconstitution, dilution, and drug waste.
• Fructose replacement may offer a targeted labeling and patient-population advantage.
• Polysorbate 80 optimization is more commercially practical than immediate replacement with an unfamiliar surfactant.
• A conventional generic vial is the simplest route, but it is exposed to price competition.
• Ready-to-use bags, dual-chamber systems, and pediatric dose formats offer stronger differentiation but carry higher regulatory and manufacturing risk.
• Excipient patents are most defensible when linked to demonstrated stability, impurity reduction, compatibility, or administration benefits.
• Orange Book listings, Paragraph IV filings, patent expiration dates, and current generic approvals determine the actual launch window and require product-specific legal review.

FAQs About Eraxis Excipients and Commercial Strategy

Does Eraxis contain sodium or preservatives?

The labeled Eraxis vial excipients are fructose, mannitol, polysorbate 80, and tartaric acid. The product is reconstituted and diluted using standard sterile infusion solutions. It is not formulated as a multidose preserved injection.

Can anidulafungin be formulated as a premixed infusion?

Potentially, but the product would need to demonstrate adequate chemical and physical stability in the selected bag, diluent, tubing, and storage conditions. A premixed product would likely require a more extensive development and regulatory package than a conventional generic vial.

Would removing fructose create a meaningful market advantage?

It could create a targeted advantage for patients with hereditary fructose intolerance or institutions seeking to minimize unnecessary excipient exposure. The commercial value would depend on whether the replacement system improves stability or administration performance without increasing cost.

Can a generic manufacturer use the same excipients as Eraxis?

A generic manufacturer can generally use the same excipients if the formulation meets applicable sameness, quality, safety, and regulatory requirements and does not infringe an enforceable patent claim. The Orange Book and relevant patent claims control the legal analysis.

Is anidulafungin suitable for an oral reformulation strategy?

No conventional oral strategy is commercially attractive because anidulafungin has poor oral bioavailability. Development would require a major delivery-system intervention, such as absorption enhancement or targeted gastrointestinal delivery, with substantial clinical and regulatory risk.

References

1. U.S. Food and Drug Administration. (2023). Eraxis (anidulafungin) for injection prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., Zaoutis, T. E., & Sobel, J. D. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50.
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).